This guide separates the two
Sathiyamoorthy, K., Mills, E., Franzmann, T
As a result, dulaglutide activates the GLP-1 receptors in various organs, such as the pancreas
Why Some Patients Do Not Respond to GLP-1 Therapies Kanwal Fatima, PharmD, BCMAS Ron Panarotti Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, whereas others experience biologically driven GLP-1 resistance
These address the specific nutritional gaps created by reduced food intake and GI-related losses during treatment
Switch to 500 mcg every other morning (EOD) as soon as Phase 1 effects are observed The every-other-day schedule reduces cumulative exposure while maintaining metabolic benefits Monitor how your body responds: appetite suppression should persist between doses at this frequency The shift from daily to EOD is not optional once effects are felt